What is Torigen Pharmaceuticals?
Torigen Pharmaceuticals Inc. operates at the intersection of veterinary medicine and advanced oncology, focusing on the development of affordable, personalized cancer vaccines for companion animals. The company's core technology utilizes a pet-patient's own tumor tissue to create a bespoke vaccine, enabling the immune system to recognize and combat tumor-associated antigens. This approach, supported by over a decade of pre-clinical research, aims to facilitate the reversal of immune senescence in animals. By providing a novel alternative to traditional veterinary oncology treatments, Torigen is carving out a distinct market niche, effectively bridging the gap between complex human-grade biologics and accessible veterinary care.
How much funding has Torigen Pharmaceuticals raised?
Torigen Pharmaceuticals has raised a total of $16.1M across 2 funding rounds:
Series A
$3.1M
Series A
$13M
Series A (2019): $3.1M with participation from Connecticut Innovations
Series A (2022): $13M led by Gaingels, Connecticut Innovations, and Emerald Development Managers
Key Investors in Torigen Pharmaceuticals
Gaingels
Gaingels is a prominent investment syndicate focused on supporting LGBTQ founders and allies, providing capital and board-level advisory services to high-growth companies across various sectors.
Connecticut Innovations
Connecticut Innovations serves as the state's strategic venture capital arm, offering equity financing and guidance to help bioscience and technology companies scale their operations.
Emerald Development Managers
Emerald Development Managers is a venture capital firm specializing in life sciences and engineering, providing strategic capital to teams solving complex real-world problems.
What's next for Torigen Pharmaceuticals?
With the recent influx of $13M, Torigen Pharmaceuticals is poised to accelerate its clinical development pipeline and broaden the commercial availability of its veterinary cancer biologics. The strategic focus will likely shift toward scaling manufacturing capabilities and expanding the reach of its personalized vaccine platform to a wider network of veterinary oncology practices. As the company moves into this next phase of growth, it will continue to leverage its scientific foundation to address the growing demand for effective, non-invasive cancer therapies in the pet health sector. The ongoing support from its investor base provides the necessary runway to navigate regulatory pathways and solidify its leadership in the emerging field of veterinary immuno-oncology.
See full Torigen Pharmaceuticals company page
